Reuters logo
BRIEF-Karyopharm Therapeutics's study will not reach statistically significant improvement in primary endpoint
March 2, 2017 / 9:24 PM / 9 months ago

BRIEF-Karyopharm Therapeutics's study will not reach statistically significant improvement in primary endpoint

March 2 (Reuters) - Karyopharm Therapeutics Inc:

* Karyopharm Therapeutics Inc - study will not reach statistically significant improvement in primary endpoint

* Karyopharm Therapeutics Inc - Karyopharm and DSMB agreed that patients would be permitted to continue on selinexor ARM or PC ARM, as applicable

* Karyopharm - plans to continue clinical development of selinexor in aml through investigator sponsored trials in multiple combination regimens

* Karyopharm - announced results of interim analysis of phase 2 sopra study evaluating single agent selinexor in relapsed/refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below